CINCINNATI / May 20, 2024 / Business Wire / Stockholders of Chemed Corporation (NYSE:CHE) today elected a slate of 10 directors at the Company’s 2024 annual stockholders’ meeting.
Stockholders ratified the continuation of PricewaterhouseCoopers LLP as the Company’s independent accountants for 2024. Stockholders also approved Chemed’s executive compensation. In addition, stockholders voted against the stockholder proposal on ratification of termination pay.
Dividend Declared
Following the stockholders’ meeting, Chemed’s Board of Directors declared a quarterly cash dividend of 40 cents per share on the Company’s capital stock, payable on June 18, 2024, to stockholders of record as of May 30, 2024. This represents the 212th consecutive quarterly dividend paid to stockholders in Chemed’s 53 years as a public company.
Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care, and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.
Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.
Last Trade: | US$571.44 |
Daily Change: | -2.36 -0.41 |
Daily Volume: | 28,132 |
Market Cap: | US$8.570B |
July 24, 2024 April 24, 2024 March 13, 2024 February 27, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB